Virological characteristics of the SARS-CoV-2 XEC variant

Yu Kaku¹, Kaho Okumura², Shusuke Kawakubo¹, Keiya Uriu¹, Luo Chen³, Yusuke Kosugi⁴, Yoshifumi Uwamino⁵, Mst Monira Begum⁶, Sharee Leong⁶, Terumasa Ikeda⁶, Kenji Sadamasu⁷, Hiroyuki Asakura⁷, Mami Nagashima⁷, Kazuhisa Yoshimura⁷; Genotype to Phenotype Japan (G2P-Japan) Consortium; Jumpei Ito⁸, Kei Sato⁹

Affiliations

¹ Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
² Faculty of Liberal Arts, Sophia University, Tokyo, Japan.
³ Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.
⁴ Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
⁵ Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
⁶ Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
⁷ Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
⁸ Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
⁹ Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Collaboration Unit for Infection, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK. Electronic address: KeiSato@g.ecc.u-tokyo.ac.jp.

PMID: 39521009
DOI: 10.1016/S1473-3099(24)00731-X

Virological characteristics of the SARS-CoV-2 XEC variant

Yu Kaku et al. Lancet Infect Dis. 2024 Dec.

. 2024 Dec;24(12):e736.

doi: 10.1016/S1473-3099(24)00731-X. Epub 2024 Nov 6.

Authors

Affiliations

¹ Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
² Faculty of Liberal Arts, Sophia University, Tokyo, Japan.
³ Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.
⁴ Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
⁵ Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
⁶ Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
⁷ Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
⁸ Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
⁹ Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Collaboration Unit for Infection, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK. Electronic address: KeiSato@g.ecc.u-tokyo.ac.jp.

PMID: 39521009
DOI: 10.1016/S1473-3099(24)00731-X

No abstract available

PubMed Disclaimer

Conflict of interest statement

JI declares consulting fees and honoraria for lectures from Takeda. KSat declares consulting fees from Moderna Japan and Takeda; and honoraria for lectures from Moderna Japan and Shionogi. The other authors declare no competing interests. YKa and KO contributed equally to this study. This study was supported in part by AMED ASPIRE Program (JP24jf0126002 to G2P-Japan Consortium and KSat); AMED SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers “UTOPIA” (JP243fa627001h0003 to KSat); AMED SCARDA Program on R&D of new generation vaccine including new modality application (JP243fa727002 to KSat); AMED Research Program on Emerging and Re-emerging Infectious Diseases (23fk0108583 and JP24fk0108690 to KSat); JST PRESTO (JPMJPR22R2 to YU; JPMJPR22R1 to JI); JSPS KAKENHI Fund for the Promotion of Joint International Research (International Leading Research; JP23K20041 to G2P-Japan Consortium and KSat); JSPS KAKENHI Grant-in-Aid for Early-Career Scientists (JP23K14526 to JI); JSPS Research Fellow DC1 (23KJ0710 to YK); JSPS KAKENHI Grant-in-Aid for Scientific Research A (JP24H00607 to KSat); Mitsubishi UFJ Financial Group Vaccine Development Grant (to JI and KSat); the Cooperative Research Program (Joint Usage/Research Center program) of Institute for Life and Medical Sciences, Kyoto University (to KSat); the Grant for International Joint Research Project of the Institute of Medical Science, the University of Tokyo (to TI and KSat).

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Virological characteristics of the SARS-CoV-2 XEC variant

Affiliations

Virological characteristics of the SARS-CoV-2 XEC variant

Authors

Affiliations

Conflict of interest statement

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous